The cochleovestibular system/ototoxicity/clinical issues.
It is recommended that the experiences of basic science with ototoxicity be applied to the development of specific clinical strategies for the treatment of the cochleovestibular complaints of hearing loss, tinnitus, vertigo, and ear blockage. The treatment goals are to maintain/improve function, namely, hearing and balance, as well as to control aberrant auditory and vestibular phenomena, for example, tinnitus and vertigo originating within the peripheral and/or central cochleovestibular system. It is hypothesized that a "common" neurochemical basis for "toxicity" exists, whatever the primary toxic etiology. It is also recommended that the neurochemical mechanisms of neuroprotection and apoptosis be considered for investigations of ototoxicity. Furthermore, it is suggested that ototoxicities are reflected in clinical manifestations of sensory cochleovestibular complaints of hearing loss, tinnitus, and vertigo, and affect complaints of stress, pain, and neuropsychiatric disorders.
Shulman
A
A
Martha Entenmann Tinnitus Research Center, Health Science Center at Brooklyn, State University of New York 11203, USA. metrc@inch.com
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D003638:Deafness / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy; D007758:Ear, Inner / Q000187:drug effects / Q000502:physiology*; D006198:Hair Cells, Auditory / Q000187:drug effects / Q000502:physiology; D006801:Humans; D017382:Reactive Oxygen Species / Q000502:physiology; D014012:Tinnitus / Q000175:diagnosis / Q000188:drug therapy; D014717:Vertigo / Q000175:diagnosis / Q000188:drug therapy
D000305:Adrenal Cortex Hormones; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D017382:Reactive Oxygen Species; D002945:Cisplatin